Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
Lorlatinib’s Unique Adverse Event Profile
Key Themes:
Notable Insights:
Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia
BMI Screening Overlooks Excess Adiposity in Children Without Obesity
September 8th 2025While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.
Read More
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More